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Glucocorticoids are often required for adequate control of inflammation in
many serious inflammatory diseases; common indications for long-term
treatment include polymyalgia rheumatica, giant cell arteritis, asthma and
chronic obstructive pulmonary disease. Long-term glucocorticoid therapy is,
however, associated with many adverse effects involving skin, gastro-
intestinal, eye, skeletal muscle, bone, adrenal, cardio-metabolic and
neuropsychiatric systems. This balance between benefits and risks of
glucocorticoids is important for clinical practice and glucocorticoid-related
adverse effects can significantly impair health-related quality of life.
Understanding the nature and mechanisms of glucocorticoid-related adverse
effects may inform how patients are monitored for toxicity and identify those
groups, such as older people, that may need closer monitoring. For clinical
trials in diseases commonly treated with glucocorticoids, standardised
measurement of glucocorticoid-related adverse effects would facilitate future
evidence synthesis and meta-analysis.
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Introduction
The glucocorticoids (GCs) are steroid hormones produced by the adrenal cortex.
A certain constitutive level of circulating cortisol (endogenous GC) is required
to maintain health. Cortisol levels increase during the physiological stress
response, eliciting a multitude of systemic effects. Although the effects of the
stress response may be adaptive in the short term, the elevation of GC levels is
deleterious over the longer term. Overproduction of cortisol results in
characteristic multi-system effects including hypertension, diabetes, accelerated
atherosclerosis, electrolyte disturbance, fat redistribution, osteoporosis, skin
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thinning, impaired healing and muscle wasting (Table 1 ).
Table 1
AQ1
Risk factors and monitoring tests for glucocorticoid-related adverse effects
GC-related
adverse effects:
organ system
Effects Risk factors
Possible
monitoring test
or intervention
Skin
– Thinning
– Bruising
– Impaired healing
– Older age
– Comorbidities
(diabetes or where
skin integrity is
compromised)
– High cumulative
doseGC dose
– Confocal laser
microscopy
– Ultrasound
– Evaporimetry
– Optical
coherence
tomography
– Dermaphot®
imaging
Gastro-intestinal – Ulceration– Impaired healing
– Older age
– Cotreatment with
NSAIDs
– High daily and
cumulative doseGC
dose
– Haemoglobin
levels
– Prophylactic
gastroprotective
treatment if
clinically
indicated
Eye – Cataract– Glaucoma
– Older age
– High cumulative
doseGC dose
– Eye
examination
including
tonometry
Skeletal muscle – Myopathy
– Older age
– Physically
inactive
– High cumulative
doseGC dose
– Muscle
strength testing
– Muscle biopsy
– CT/MRI scan
for muscle cross-
sectional area
– Patient
questioning
Bone – Osteoporosis– Osteonecrosis – Older age
– Bone mineral
density
– Bone
protection
therapy
Adrenal
– Suppression of
endogenous GC
production
– Basal cortisol
levels <386 nmol/L
– Total GC dose
>8.5 g
– GC treatment
duration
– Slow reduction
in GC dose
– ACTH
stimulation test
a
a
a
a
a
a
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>19 months
Metabolic
– Diabetes
– Weight gain
– Hyperglycaemia
– Older age
– Cumulative
doseGC dose
≥1.8 g
– Female
– Family history
– Fasting blood
glucose test
– Oral glucose
tolerance test
– Weight and
height
Cardiovascular
disease
– Accelerated
atherosclerosis
– Hypertension
–
Hypercholesterolaemia
– High cumulative
doseGC dose
– Presence of CVD
risk factors prior to
GC therapy
– Hypertension
– Screening for
hypertension
pre-GC
treatment
– Blood pressure
– Lipid profile
Neuropsychiatric
– Anxiety
– Depression
– Psychosis
– WomenFemale
– Alcoholism
– Family history of
depression
– High doseGC
dose
– Patient
questioning
– Questionnaires
–
Pharmacotherapy
Infection – Impaired neutrophilfunction
– Additional
immunosuppressive
treatments
None– None
Low– Low
threshold of
suspicion for
investigation of
sepsis
See clinical practice guidelines from EULAR and/or BSR
Exogenous GCs have been utilised since the 1950s [ 1 ] for their potent
immunosuppressive and anti-inflammatory effects; the most commonly
prescribed oral GC is prednisolone or its pro-drug prednisone. Long-term GC
therapy is associated with many adverse effects (AEs) that are often related to
daily or cumulative GC dose; hence, the development of ‘steroid-sparing’
agents for many autoimmune rheumatic diseases, such as rheumatoid arthritis
(RA). Although steroid-sparing agents have substantially reduced the amount of
GCs prescribed in RA, low-dose GC therapy is still commonly used as part of
combination therapy [ 2 ]. For polymyalgia rheumatica (PMR) and giant cell
arteritis (GCA), however, GCs are still the cornerstone of therapy and often
given as monotherapy. The short-term benefit of GCs in controlling the
inflammatory disease is traded off against the risk of AEs (and resulting impact
on health-related quality of life; HRQoL) in the longer term. Many GC-related
a
a
a
a
a
a
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AEs are very costly; e.g. $18,357.90 for a bone fracture per year per episode
[ 3 ]. Measurement of GC-related AEs, and their impact on patients, is important
for establishing both the overall clinical effectiveness and the cost-effectiveness
of any treatment strategies intended to reduce total GC exposure. Reducing GC-
related AEs is also an important part of the rationale for developing novel
diagnostics for GCA and PMR, as well as other serious diseases requiring long-
term GC therapy.
Glucocorticoid-Related Adverse Effects
It is difficult to quantify the precise risk of GC-related AEs because of
confounding by indication: because of the greater burden of inflammation,
patients with more severe disease are both more likely to receive higher doses
of GCs, and at greater risk of complications such as accelerated atherosclerosis
and myopathy. These complications could be due to the disease as well as due
to GCs. Here we use the term ‘GC-related’ AE to acknowledge this potential
confounding, in contrast to ‘GC toxicity’ by which we mean the toxicity
directly caused by GCs.
Although single randomised controlled trials (RCTs) are not usually powered to
detect significant reductions in any particular GC-related AE, if a common set
of secondary outcome measures (core outcome measurement set) were
employed across all RCTs for a particular condition, meta-analysis may provide
rich information that could inform clinical practice [4 ]. Indeed, there have been
recent proposals for ‘core adverse events’ to be considered in formulating core
outcome measurement sets in some disease areas [ 5 ]. It may even be possible
to meta-analyse across different indications [ 6 ]. In order to select the most
meaningful outcome measures, however, it is necessary to understand the nature
and pathophysiology of GC toxicity. Here, rather than producing an exhaustive
review, we focus on the AEs that are not so well covered by existing guidelines:
skin, wound healing and gastric ulcers, eye, myopathy, bone, adrenal
suppression, diabetes mellitus, weight gain, cardiovascular disease,
neuropsychiatric, and infection.
Nature and Pathophysiology of Glucocorticoid
Toxicities
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Skin
The cutaneous manifestations of GC excess include telangiectasiae, atrophic
striae, easy bruising, poor wound healing, increased transepidermal water loss
and skin thinning [ 7 , 8 ]. Skin thinning was reported in 85 % of young
hypercortisolaemic patients and is a characteristic factor that suggests
Cushing’s syndrome rather than simple obesity [ 9 ]. The mechanisms of GC
toxicity to the skin include reduced epidermal keratinocyte/dermal fibroblast
proliferation, impaired collagen processing and decreased extracellular matrix
protein/epidermal lipid expression [ 10 , 11 ].
Effects of GC on the skin can include dryness, itching, burning and eczema
[ 12 ]. In a survey of patients receiving oral GC therapy for 60 days or more,
60 % of participants reported skin changes that were bothersome [ 13 ]. Skin
changes can have substantial psychological effects and therefore affect patients’
HRQoL [ 14 ]. Current EULAR recommendations do not advocate routine
monitoring of skin thinning for low-dose oral GCs taken for less than 6 months
[ 2 , 15 ]. However, although skin thinning/bruising was reported by 70 % of GC
users receiving ≥10 mg prednisone daily for 18 months, skin thinning/bruising
and acne were also significantly associated with longer durations of low-dose
(≤7.5 mg/day prednisone) GC treatment [ 13 ]. In a survey of 213 asthma
specialists, skin thinning/bruising was the second most frequently reported AE
relating to inhaled GC use, particularly in older patients [ 16 ]. Besides age,
other risk factors for GC-related skin toxicity include comorbidities such as
diabetes [ 17 ] where skin integrity is already compromised [ 18 , 19 ].
Given the paucity of detailed data on skin changes in those taking GCs for
rheumatic disease, it is suggested that skin thinning is assessed in future RCTs
in this area. Methods to accurately evaluate GC-induced skin atrophy include
confocal laser microscopy, ultrasound, optical coherence tomography (OCT)
and evaporimetry [ 20 , 21 ]. Although readily accessible, the Dermaphot®
imaging and scoring system is more subjective and less sensitive than OCT for
detection of subclinical epidermal thinning [ 20 ] with feasibility limited to
monitoring visible GC-related skin AE such as telangiectasias.
There is the potential to use topical agents to reduce the unwanted effects of
GCs on the skin [ 22 ]; ‘steroid-sparing’ (immunosuppressive or
14/04/2015 11:29e.Proofing
Page 7 of 27http://eproofing.springer.com/journals/printpage.php?token=tied1_9h6GfkA1bz4BdhSLmRr-9cVV1LwfAgIK7u4rw
immunomodulatory) agents may be given either topically or systemically [ 23 ].
Selective GC receptor agonists (SEGRAs) have also been suggested for topical
use [ 24 ], but no clinical trial data are yet available.
Wound Healing and Gastric Ulcers
Chronic wounds and associated infections represent a substantial economic
burden, costing the US >$25 billion annually and particularly affecting older
people [ 25 ]. GCs disrupt multiple signalling pathways that are delicately
orchestrated during normal repair, causing dysregulation of intercellular cross-
talk, proliferation, differentiation, migration, re-epithelialisation and
extracellular matrix remodelling [ 10 , 26 , 27 ]. Gastric ulceration is an
important GC-related AE, particularly in individuals co-prescribed non-
steroidal anti-inflammatory drugs (NSAIDs) [10 , 28 ]. Older patients are at
higher risk of delayed wound healing [ 29 , 30 ], suggesting that this group may
require greater caution. Even low-dose prednisone is associated with gastric
ulceration when taken in the long term, although some of the data pre-dates
widespread use of modern gastroprotective therapy [ 31 ]. Since wound healing
and peptic ulcers are important to both patients and rheumatologists [ 32 ],
EULAR recommendations advise routine monitoring (e.g. checking
haemoglobin levels) in patients exposed to long-term GC therapy and
prophylactic gastroprotective treatment (e.g. proton pump inhibitors) where
necessary [ 15 ]. However, gastroprotective treatment remains underused in
older patients prescribed GC therapy in the community [ 33 ].
Eye
Cataract and glaucoma constitute a significant burden on national healthcare
costs [ 34 ]. Cataract surgery costs €700 per eye in Europe [ 35 ] and €5000 per
quality-adjusted life year gained with both eyes operated on [ 36 ]. For
glaucoma, the annual average cost per patient is €700–1000 based on disease
severity [ 37 ].
GC therapy is associated with both cataract (particularly posterior subcapsular
cataract) and glaucoma [ 28 , 35 ]. In a study using the national database of the
German Collaborative Arthritis Centre, the prevalence of self-reported cataract
was higher for any GC users (including those taking <5 mg prednisone daily)
whereas the prevalence of self-reported glaucoma was only increased in those
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taking >7.5 mg daily [ 38 ]. In a nested case-control analysis within a historic
RA cohort, long-term, low-dose prednisone treatment was significantly
associated with development of cataract [ 31 ].
Recommendations regarding ocular monitoring for GC toxicity vary. Previous
EULAR recommendations advise baseline screening and ongoing monitoring
for both cataract and glaucoma in patients receiving GCs for rheumatic disease
[ 39 ], but for low-dose GC therapy only baseline screening for glaucoma is
recommended [ 15 ]. For patients with systemic lupus erythematosus (SLE)
receiving long-term GC therapy, at least a baseline eye assessment is
recommended [ 40 ]. However, a chart review of 170 patients with SLE taking
long-term GC therapy revealed that 20 % had never undergone an eye
assessment; of those who had ever had an eye assessment, 29 % had cataract
and 3 % glaucoma; development of cataract was associated with age, disease
duration and cumulative GC dose [ 34 ].
Limitations of routinely collected clinical data such as this include
screening/detection bias: both overdetection (since cataract is extremely
common in older people) and underdetection (for example, in the UK ocular
monitoring tends to be carried out by opticians, but intraocular pressure
monitoring is not funded except in those with defined risk factors for glaucoma;
consequently, tonometry is not always performed). Since both glaucoma and
cataract are readily treatable, there are strong arguments for implementation of
systematic ocular screening in long-term GC therapy.
Myopathy
GC-induced myopathy typically affects the proximal skeletal muscles and is
characterised by weakness and atrophy [ 41 ]. Multiple complex mechanisms are
involved [ 42 ]. GCs inhibit the pathways involved in protein synthesis, such as
transportation of amino acids into the muscle, and also increase muscle
proteolysis through the ubiquitin/proteasome pathway. Both patients with
rheumatic diseases on GC therapy and rheumatologists listed myopathy
amongst the top 10 most worrisome GC-induced AE [ 32 ].
GC-related myopathy can be difficult to distinguish clinically from the
symptoms and consequences of rheumatic diseases themselves, such as atrophy
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related to muscle disuse. In GCA patients receiving high-dose oral GCs,
myopathy was listed as an AE in 3/39 patients in a 2-year trial [ 43 ] but in 0/27
patients in a 78-week trial [ 44 ]. Yet in a third trial, 20/21 GCA patients
reported ‘subjective muscle weakness’ [ 45 ]. In an observational study of
patients with PMR using the Rochester Epidemiology Project database, 6/232
(2.6 %) patients with PMR had myopathy (5/175 of those receiving GCs and
1/57 of those receiving NSAIDs only); myopathy was defined as ‘physician’s
diagnosis supported by documented proximal muscle weakness’ [ 46 ].
Interpretation is hampered by the lack of standardised definitions and
monitoring for GC-related myopathy in clinical practice. EULAR only
recommends that GC-related muscle weakness should be assessed ‘through
questioning’ at the start and end of the treatment in clinical trials [ 15 ]. It is
unclear whether this is a sufficiently sensitive monitoring method.
Muscle strength tests that have been used to assess weakness in patients
receiving GCs include maximum voluntary contraction of the quadriceps [47 ].
Functional tests include the stepper test (number of steps completed in 10 s),
although reliability and variability data is limited [ 48 ]. Muscle biopsies
arguably represent a gold standard for tissue changes, with characteristic
changes of GC myopathy including reduced cross-sectional area of type II
muscle fibres, in contrast to disuse atrophy which preferentially affects type I
fibres [ 47 ]. However, there are logistical difficulties in obtaining muscle
biopsies; imaging is a logical alternative for measuring muscle atrophy. In a
small study, CT and MRI gave equivalent results for detecting a reduction in
mid-thigh muscle cross-sectional area (CSA) following 20–60 mg/day GC
treatment [ 49 ]. Higher cumulative GC doses are associated both with reduced
muscle strength [ 50 ] and with reduced mid-thigh muscle CSA [ 49 ]. Other risk
factors for GC-related myopathy include older age and physical inactivity [51 ].
Strategies for treating GC-related myopathy, if detected, include GC dose
reduction if possible [ 50 ] and exercise programmes [ 52 , 53 ].
Bone
Osteoporosis is frequently highly ranked as a GC-mediated AE of significant
concern to both patients and clinicians [ 13 , 32 ]. Bone mineral density (BMD)
decreases even with low-dose GCs [ 54 , 55 ] and fracture risk increases with
cumulative GC therapy [ 13 ]. Fractures are associated with substantial
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morbidity and associated healthcare costs [ 56 ], particularly in the elderly [ 57 ].
Current recommendations advise assessment of risk factors for
osteoporosis/fracture, for example by using the FRAX tool; while there is good
evidence for several pharmacological treatments such as bisphosphonates
[ 58 ••], this type of high-level evidence was not available recommendations
regarding monitoring and for non-pharmacological treatments [ 59 ].
GC-mediated osteoporosis results largely from decreased bone formation, in
contrast to postmenopausal osteoporosis which is characterised by increased
bone turnover [ 60 ]. GCs inhibit osteoblast activity and direct osteoblast
precursor cell differentiation towards adipogenesis rather than
osteoblastogenesis [ 61 , 62 ]. Concomitantly, osteoclast differentiation is
promoted while apoptosis is suppressed [ 63 ], leading to decreased bone mass,
impaired bone microstructure and increased fracture risk.
A recent systematic review of observational studies of long-term oral GC
therapy found that in over 80 % of these studies, fewer than 40 % of patients
received BMD testing or bone-protecting pharmacotherapy [ 64 ].
Adrenal Suppression
Adrenocorticotropic hormone (ACTH) is released from the anterior pituitary
gland and stimulates cortisol synthesis in the adrenal cortex. Cortisol acts via
the GC receptor in a physiological negative-feedback loop on the hypothalamo-
pituitary-adrenal (HPA) axis to inhibit further cortisol synthesis [ 65 ].
Exogenous GCs inhibit the HPA axis in the same way [ 10 ]. Long-term GC
treatment may cause sustained low ACTH levels, leading to adrenal atrophy
[ 66 ]. GC-related adrenal suppression may cause clinically significant adrenal
insufficiency in the face of physiological stressors such as intercurrent illness or
surgery [ 67 ].
About half of patients receiving long-term GCs fail an ACTH stimulation test,
which measures cortisol levels following injection with synthetic ACTH [68 ,
69 ]. A large longitudinal study conducted between 1984 and 2009 found that
49 % of GCA patients failed an ACTH test when their GC dose reached
5 mg/day [ 68 ]. Amongst these patients, it took a mean duration of 14 months
for adrenal function to return to normal. Moreover, in RA patients prescribed
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low-dose GC treatment (7.5 mg/day prednisolone) for 3 months, cortisol levels
pre-, 30 min post- and 60 min post-ACTH test were reduced by 28%, 34% and
35 %, respectively [ 69 ]. EULAR does not currently recommend monitoring
adrenal function in routine clinical practice during either low- or high-dose GC
treatment [15, 70]. However, it is recommended that in patients taking >7.5 mg
prednisolone-equivalent daily for >3 weeks, clinicians should be aware of the
risk of adrenal suppression and that a slow reduction in dose should be followed
prior to cessation [ 70 ••]. Risk factors for iatrogenic adrenal suppression in one
study included a total GC dose >8.5 g, a duration of treatment >19 months and
basal cortisol levels <386 nmol/L [ 68 ]. However, interpretation of ACTH
stimulation test results and definition of what is a clinically significant
suppression is not always straightforward. The low-dose ACTH test (1 µg of
tetracosactide) is more sensitive than the standard 250 µg test [ 71 , 72 ].
Suggestions for screening for iatrogenic adrenal suppression have been
published elsewhere [ 73 ••].
Diabetes Mellitus
Diabetes mellitus (DM) is the top most worrisome GC-related AE amongst
rheumatologists and third most worrisome amongst patients with rheumatic
diseases [ 32 ]. Insulin resistance (IR) precedes development of DM and is
induced by GCs via several mechanisms [ 74 ]. These include increased
transactivation of gluconeogenesis enzymes which increase hepatic glucose
synthesis and glycogen deposition. This results in hyperglycaemia [10 ],
inhibition of insulin signalling in fat, liver and muscle cells by suppression of
insulin receptor substrate transcription [ 74 ], pancreatic β-cell dysfunction
mediated via the GC receptor [ 75 ] and increased proteolysis and lipolysis,
causing increased release of amino acids and free fatty acids [ 74 ]. Given that
DM can cause further health complications and increased mortality [76 ], the
prevention of this GC-mediated condition is crucial.
Evidence suggests that the risk of developing DM is dose dependent, with few
events of GC-induced DM reported in patients on low-dose GCs [ 15 , 77 ] but
more in patients on medium- and high-dose GCs. In two separate studies, 7/124
of PMR patients and 2/40 of RA patients receiving an average daily dose of
10 mg prednisolone/day developed DM [ 46 , 78 ]. Moreover, 7/19 of GCA
patients on high-dose GCs developed DM, and a further 2/19 developed glucose
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intolerance [ 43 ]. High-dose GCs induced DM in 16/127 of patients with SLE
[ 79 ].
According to EULAR recommendations, patients with rheumatic diseases
taking long-term or high-dose GC should be monitored by measuring fasting
blood glucose levels and through an oral glucose tolerance test (OGTT) at the
start and end of therapy [ 15 , 70 ••]. In PMR and GCA, the British Society for
Rheumatology (BSR) simply recommends 3-monthly glucose testing [ 80 , 81 ].
If a patient already has diabetes or pre-diabetes at the start of GC therapy, very
careful monitoring should be implemented during treatment. Older patients and
those with a family history of DM appear to be at increased risk [ 46 , 79 ].
Weight Gain
Weight gain affects about 80 % of patients receiving long-term high-dose GCs
[ 13 ]. A study of low-dose GC reported weight gain in fewer (4/93) patients
[ 77 ]. Weight gain contributes to the risk of GC-induced DM [ 74 ]; EULAR and
the BSR recommend monitoring weight during follow-up [ 15 , 80 , 81 ]. For
patients with rheumatic diseases, weight gain ranks highly amongst worrisome
GC-related AE [ 32 ] and anecdotally can have a major impact on HRQoL. It is
unknown whether patients’ concern of weight gain reduces adherence to GC
therapy.
Cardiovascular Disease
Cardiovascular disease (CVD) is associated both with inflammatory rheumatic
disease and with GC therapy [ 82 – 85 ], and is of major concern to patients and
rheumatologists [ 32 ]. Cardiovascular events (CVE) are associated with
cumulative GC dose [ 86 ], but clinical trials data on low-dose GCs in RA
appear reassuring, at least over the short term [ 77 , 78 , 86 , 87 ]. EULAR
recommend that carotid intima-media thickness (IMT; an indicator of
atherosclerosis) should be measured at the start and end of clinical trials [ 15 ],
although this is problematic in GCA/PMR since active GCA may itself cause an
increase in IMT [ 87 ]. Analysis of routinely collected clinical data [ 88 ] may
yield more precise estimates of the magnitude of elevated risk of CVE in GC-
using versus non-GC-using patients with rheumatic disease, but this does not
address the problem of confounding by indication (i.e. disease severity, which
is difficult to measure precisely). Furthermore, in GCA, the disease itself might
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directly cause CVE [ 89 ]. EULAR and the BSR recommend screening for
hypertension and other CVD risk factors prior to commencing GC therapy in all
patients with inflammatory diseases [ 15 , 70 ••, 81 ]. It could be argued that
patients receiving long-term GCs should have a lower threshold for starting
cholesterol-lowering medication, but this must be balanced against the burden
of polypharmacy for patients.
Neuropsychiatric
GC treatment has been associated with anxiety, depression, mood swings, sleep
disturbances and psychosis, but prediction is difficult. Regarding low-dose GC,
the existing data appear reassuring [ 78 , 90 , 91 ] and it is important to bear in
mind the benefits of effectively treating disease; depression may be ameliorated
by low-dose GCs in RA [ 77 ]. In contrast, patients receiving high-dose GCs
appear more likely to experience neuropsychiatric symptoms, although
confounding by indication limits interpretation of existing data. In a meta-
analysis, psychosis and mood swings were the most common GC-related AE
(20 %) in RA, PMR and inflammatory bowel disease patients [ 92 ]. The data,
however, are plagued by inconsistency in defining and assessing
neuropsychiatric AEs, and the severity of the reported neuropsychiatric AE is
often unclear [ 43 – 45 ]. In clinical trials, standardised assessment tools would
add valuable data. A recent study identified that diabetic women taking GCs
were twice as likely to report depressive symptoms as those not taking GCs,
when assessed using the Hospital Anxiety and Depression Scale [93 ].
Neuropsychiatric disturbances can occur as early as the first week of GC
treatment or even after treatment has ceased [ 94 ]. If suspected, a reduction in
GC dose is recommended (if possible) and pharmacological intervention may
also be warranted [ 94 ].
Infection
Infections are less common in RA patients receiving low-dose GC: 3–32 % [ 77 ,
78 , 91 ] compared to older patients being treated for PMR or GCA 10–52 %
[ 43 , 46 , 95 ]. With GC treatment, neutrophils show reduced adhesion to
endothelial monolayers [ 96 ]. Laboratory analysis of blood samples from GC-
treated patients tends to reveal a high neutrophil count since the GCs cause the
neutrophils to demarginate. Detection of sepsis can also be delayed because of
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these GC-induced changes in neutrophil count and because GCs inhibit the
febrile response to infection. Patients receiving GCs should undergo the same
precautions as those taking other immunosuppressants, such as vaccination and
a low threshold of suspicion of infection [ 70 ••]. Older age and other GC-related
complications such as DM, skin thinning and impaired healing are likely to
confer additional risk.
Health-Related Quality of Life and Utility
While it may be important for trials of GC-sparing agents to accurately measure
every possible GC-related AE (Table 1 ), this is unlikely to be feasible for large
pragmatic trials or for longitudinal observational studies of representative
patients with GCA/PMR because the burden of assessments might be too great
for older, frailer patients. Any core adverse events outcome measurement set
relating to GC therapy would need to take feasibility and parsimony into
consideration.
When modelling the clinical and cost-effectiveness of novel diagnostics or
therapeutics where ‘steroid-sparing’ is a major aim, it is challenging to
separately include every GC-related AEs, and all of their consequences on
patients’ health state and health care utilisation. However, rheumatology
registries (e.g. BSRBR, ACR RCR, etc.) and triallists could consider collecting
HRQoL data that would reflect GC therapy as well as disease-related AEs. This
would be attractive because it would incorporate the trade-off between
medication benefits and AEs that is well understood by patients undergoing
treatment. Any instrument measuring HRQoL specifically in GC-treated
diseases would require robust qualitative work as a foundation. Until such
instruments are developed, established HRQoL instruments such as the EQ-5D
available from www.euroqol.org [ 97 ] or the SF-6D available from
https://www.shef.ac.uk/scharr/sections/heds/mvh/sf-6d [ 98 ] could be employed
to capture the combined impact of all GC-related AE in a particular population.
EQ-5D is the most commonly used HRQoL instrument and has been found to be
a responsive measure in detecting deterioration in health in a number of health
conditions including RA [ 99 ]. SF-6D is generated from the SF-36 or the SF-12
questionnaires, which are widely used in clinical studies as a measure of general
health, and have been shown to be appropriate for patients with RA [ 100 , 101 ].
The descriptive systems of both EQ-5D and SF-6D capture overall health and
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should incorporate both health benefits and adverse events. EQ-5D was shown
to identify adverse events to drug therapy and comorbidities [ 102 , 103 •] while
condition-specific health measures could not [ 104 ]. Another advantage of those
HRQoL instruments is that they can be used to generate utility and ultimately
quality-adjusted life years, which is the primary outcome for economic
evaluation in the NICE reference case [ 105 ]. The combination of answers to
EQ-5D (or respectively SF-6D) leads to a health profile that can be converted
into a utility using standard weights representing a societal valuation of quality
of life on a preference-based utility scale. The utility represents patients’ overall
quality of life and when multiplied by the time spent in each health state it
generates quality-adjusted life years (QALYs). The way AEs are effectively
incorporated in HRQoL as well as the relationship of AEs and health care
utilisation still needs further analysis [ 106 ]; systematically collected HRQoL
data could be combined with costs data to determine cost-effectiveness using a
decision analysis model. This may yield important information to support the
use of ‘steroid sparing’ therapies when both treatment arms achieve similar
levels of inflammatory disease control.
Conclusions
GC therapy is widespread and its risks are well known, although many of these
risks are difficult to accurately quantify from current published data. The
common theme is that risks of almost all GC-related AE increase with age. Data
from clinical trials in RA cannot necessarily be extrapolated to infer risks of GC
therapy in older people with PMR or GCA. Monitoring and mitigation of these
GC-related AE requires an understanding of the pathophysiological mechanisms
involved. The variations in arrangements for monitoring of the AEs of long-
term GC therapy contrasts with the comparatively rigid protocols developed for
monitoring of GC-sparing agents such as methotrexate, which are generally
considered safer than long-term GCs. Development and economic evaluation of
any novel diagnostic and therapeutic strategies to reduce GC-related AE will
require careful selection of relevant, validated outcome measures that capture
the impact of GC-related AE on HRQoL in order to facilitate robust clinical and
cost-effectiveness evaluation.
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